- In July 2024, Neurocrine Biosciences introduced a new sprinkle formulation of INGREZZA (valbenazine) capsules, designed to ease administration for individuals experiencing dysphagia or difficulty swallowing. This formulation allows the contents to be sprinkled on soft foods, facilitating treatment adherence for adults with tardive dyskinesia (TD) and chorea associated with Huntington's disease. The sprinkle capsules are available in 40 mg, 60 mg, and 80 mg strengths
- In May 2024, During Tardive Dyskinesia Awareness Week, Neurocrine Biosciences collaborated with various stakeholders to conduct nationwide initiatives aimed at decreasing stigma, improving recognition, and increasing routine screenings and diagnosis of TD. These efforts are part of a broader commitment to enhance awareness and support for the approximately 600,000 individuals in the U.S. living with TD
- In April 2024, The U.S. Food and Drug Administration (FDA) approved the sprinkle formulation of INGREZZA (valbenazine) capsules for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease. This approval provides a more convenient administration option for patients who have difficulty swallowing pills, potentially improving treatment adherence and outcomes
- In February 2023, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDOXR (deutetrabenazine) extended-release tablets, a new once-daily formulation indicated in adults for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). This strategy enabled company to strengthen their product offerings
- In June 2022, Mitsubishi Tanabe Pharma Corporation a member of the Mitsubishi Chemical Holdings Group, announced that MTPC is launching DYSVAL capsules 40mg (the vesicular monoamine transporter type 2 (VMAT2) inhibitor) for the treatment of tardive dyskinesia in Japan. This strategy enabled company to expand its customer base
